Aspartic Acid

Aspartic Acid

SCHEMBL135826

C[SiH2]O.N[C@@H](CC(=O)O)C(=O)O.O=C(O)[C@H]1NCCC1O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SSTR1SSTR2SSTR3SSTR5

The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 6/20 0.38
GRIK2 Q13002 3/20 0.38
SLC1A2 P43004 3/20 0.36
ARG1 P05089 3/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ARG2 P78540 1/20 0.32
CYP1A2 P05177 1/20 0.32
ALOX15 P16050 1/20 0.32
GRIA2 P42262 2/20 0.32
GRIA4 P48058 2/20 0.32
GRIK3 Q13003 2/20 0.32
GRIK5 Q16478 2/20 0.32
GRIA1 P42261 1/20 0.32
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aspartic Acid SCHEMBL8016849 0.93 GRIK1 (0.42) GRIK1GRIK2SLC1A2ARG1MEN1
Aspartic Acid SCHEMBL2880117 0.83 GRIK1 (0.33) GRIK1GRIK2GRIA2GRIA4GRIK3
Asparagine SCHEMBL8942998 0.83 GRIK1 (0.41) GRIK1GRIK2SLC1A2ARG1MEN1
SCHEMBL628704 0.82 SLC1A2 (0.50) SLC1A2ARG1MEN1KMT2AARG2
SCHEMBL2888794 0.81 SLC1A2 (0.41) GRIK1GRIK2SLC1A2ARG1MEN1
Serine SCHEMBL5057619 0.80 SLC1A2 (0.42) GRIK1GRIK2SLC1A2ARG1MEN1
Norvaline SCHEMBL28754255 0.79 SLC1A2 (0.39) GRIK1GRIK2SLC1A2ARG1ARG2
Cysteine SCHEMBL8631390 0.79 PTGS1 (0.50) GRIK1GRIK2SLC1A2ARG1MEN1
Leucine SCHEMBL6370664 0.78 SLC7A5 (0.42) GRIK1GRIK2SLC1A2ARG1
Alanine SCHEMBL7049985 0.78 SLC1A2 (0.46) SLC1A2ARG1MEN1KMT2AARG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3881819-B1 TWO-DOSAGE-FORM ESSENCE AND PREPARATION METHOD THEREFOR GUANGZHOU BIOHOPE CO LTD (CN) 2024-12-25 EP claimed
US-20230240963-A1 PIGMENT SUSPENSION AND COSMETIC AGENT PREPARED USING THE PIGMENT SUSPENSION HENKEL AG & CO. KGAA (DE) 2023-08-03 US claimed
EP-4171471-A2 PIGMENT SUSPENSION AND COSMETIC AGENT PREPARED USING THE PIGMENT SUSPENSION Henkel AG & Co. KGaA (DE) 2023-05-03 EP claimed
EP-4171499-A1 METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DERIVATIVE OF ALKYLATED SILANOL, A COLORING COMPOUND AND A POST-TREATMENT AGENT Henkel AG & Co. KGaA (DE) 2023-05-03 EP claimed
CN-110013447-B Cream for removing striae gravidarum and preparation method thereof 广州雅纯化妆品制造有限公司 2022-08-05 CN claimed
EP-3212688-B1 THERMOPLASTIC POLYURETHANE FILM FOR DELIVERY OF ACTIVE AGENTS TO SKIN SURFACES LUBRIZOL ADVANCED MAT INC (US) 2022-04-13 EP claimed
US-20220087924-A1 TWO-DOSAGE-FORM ESSENCE AND PREPARATION METHOD THEREOF Guangzhou Biohope Co., Ltd. (CN) 2022-03-24 US claimed
WO-2021259544-A2 PIGMENT SUSPENSION AND COSMETIC AGENT PREPARED USING THE PIGMENT SUSPENSION HENKEL AG & CO. KGAA (DE) 2021-12-30 WO claimed
WO-2021259543-A1 METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DERIVATIVE OF ALKYLATED SILANOL, A COLORING COMPOUND AND A POST-TREATMENT AGENT HENKEL AG & CO. KGAA (DE) 2021-12-30 WO claimed
EP-3881819-A1 TWO-DOSAGE-FORM ESSENCE AND PREPARATION METHOD THEREFOR Guangzhou Biohope Co., Ltd. (CN) 2021-09-22 EP claimed
EP-2825047-A1 PROBIOTIC/ANTIOXIDANT BLEND Revlon (US) 2015-01-21 EP claimed
WO-2013137899-A1 PROBIOTIC/ANTIOXIDANT BLEND REVLON (US) 2013-09-19 WO claimed
EP-1205184-B1 Methylsilanol hydroxyproline aspartate and palmitoyl-pentapeptide-based synergistic composition THABAUT SIMON (FR) 2009-03-11 EP claimed
EP-1646359-B1 PREPARATION FOR TOPICAL USE WITH THE FUNCTION OF COMBATING HAIR LOSS GECOMWERT ANSTALT (LI) 2007-04-25 EP claimed
EP-1646359-A1 PREPARATION FOR TOPICAL USE WITH THE FUNCTION OF COMBATING HAIR LOSS Gecomwert Anstalt (LI) 2006-04-19 EP claimed
US-20060057093-A1 Preparation for topical use with the function of combating hair loss GECOMWERT, ANSTALT (LI) 2006-03-16 US claimed
WO-2005007125-A1 PREPARATION FOR TOPICAL USE WITH THE FUNCTION OF COMBATING HAIR LOSS GECOMWERT ANSTALT (LI) 2005-01-27 WO claimed
US-20020155962-A1 Nonaqueous hair styling composition and method of use ANDREW JERGENS COMPANY, THE 2002-10-24 US claimed
EP-1205184-A1 Methylsilanol hydroxyproline aspartate-based composition Thabaut, Simon (FR) 2002-05-15 EP claimed
US-5204105-A For reducing puffiness, irritation under the eyes; plant and vegetable extracts, silicone, selenium and vitamin components CHANEL, INC. (US) 1993-04-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230240963-A1 PIGMENT SUSPENSION AND COSMETIC AGENT PREPARED USING THE PIGMENT SUSPENSION RCC1, CCNA1, TYR GRIK1 4349/4885GRIK2 4481/4885SLC1A2 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.